Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 28, 2026, 5:38 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 3,283 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Tablet Condition Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

A Relative Bioavailability Study of 100 mg Flavoxate Hydrochloride Tablets Under Fasting Conditions

NCT00992238
View directory record Official record
Conditions
Healthy
Interventions
Flavoxate Hydrochloride Tablets, 100mg, Urispas® Tablets, 100mg
Drug
Lead sponsor
Padagis LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Jul 9, 2023 · Synced Sep 28, 2026, 5:38 PM EDT
Completed Phase 3 Interventional Results available

Active Reference (Fluoxetine) Fixed-dose Study of Vortioxetine in Paediatric Participants Aged 7 to 11 Years With Major Depressive Disorder (MDD)

NCT02709655
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
Vortioxetine 10 mg/day, Vortioxetine 20 mg/day, Fluoxetine 20mg/day, Placebo
Drug · Other
Lead sponsor
H. Lundbeck A/S
Industry
Eligibility
7 Years to 11 Years
Enrollment
683 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
34
States / cities
Little Rock, Arkansas • Imperial, California • Lemon Grove, California + 29 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2022 · Synced Sep 28, 2026, 5:38 PM EDT
Completed Phase 3 Interventional

A Multicenter, Open-label Trial to Assess Subject Preference of PARCOPA, Carbidopa/Levodopa Orally Disintegrating Tablets, Compared to Conventional Carbidopa/Levodopa Tablets in Subjects With Stable Parkinson's Disease

NCT00139867
View directory record Official record
Conditions
Parkinson's Disease
Interventions
PARCOPA
Drug
Lead sponsor
UCB Pharma
Industry
Eligibility
18 Years and older
Timeline
2004
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 19, 2014 · Synced Sep 28, 2026, 5:38 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Combination of Decitabine and Temozolomide in the Treatment of Patients With Metastatic Melanoma

NCT00715793
View directory record Official record
Conditions
Malignant Melanoma
Interventions
Decitabine, Temozolomide, biopsy
Drug · Procedure
Lead sponsor
Hussein Tawbi
Other
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 2, 2017 · Synced Sep 28, 2026, 5:38 PM EDT
Completed Phase 1 Interventional Results available

Food Effect Study of Alisertib (MLN8237) in Participants With Advanced Solid Tumors or Lymphomas

NCT01898078
View directory record Official record
Conditions
Advanced Solid Tumors, Lymphoma
Interventions
Alisertib
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
3
States / cities
The Bronx, New York • Nashville, Tennessee • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 20, 2019 · Synced Sep 28, 2026, 5:38 PM EDT
Completed Phase 2 Interventional Results available

A Randomized Phase 2 Trial of TAS-114 in Combination With S-1 Versus S-1

NCT02855125
View directory record Official record
Conditions
Advanced or Metastatic Non-small Cell Lung Cancer
Interventions
TAS-114, S-1
Drug
Lead sponsor
Taiho Oncology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
6
States / cities
Loma Linda, California • Gainesville, Florida • Cleveland, Ohio + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Sep 28, 2026, 5:38 PM EDT
Completed Phase 2 Interventional

Safety and Efficacy of RX-10100 to Treat Major Depressive Disorder

NCT01273376
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
RX-10100
Drug
Lead sponsor
Rexahn Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
314 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
44
States / cities
Cerritos, California • Escondido, California • Los Angeles, California + 38 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2013 · Synced Sep 28, 2026, 5:38 PM EDT
Completed Phase 2 Interventional Results available

Phase 2, Parallel Group, Rollover Study of AKR-501 in Patients With ChronicITP Who Completed 28 Days of Study Treatment in Protocol 501-CL-003

NCT00625443
View directory record Official record
Conditions
Idiopathic Thrombocytopenic Purpura
Interventions
Blinded (placebo), Open Label (Avatrombopag tablets), Blinded (Avatrombopoag tablets)
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
12
States / cities
Anaheim, California • Bakersfield, California • Manchester, Connecticut + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2018 · Synced Sep 28, 2026, 5:38 PM EDT
Completed Phase 1Phase 2 Interventional

Sirtuin-NAD Activator in Alzheimer's Disease

NCT05040321
View directory record Official record
Conditions
Alzheimer's Disease (Incl Subtypes), Dementia
Interventions
MIB-626, Placebo
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
55 Years to 85 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Sep 28, 2026, 5:38 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Bioavailability Study of Ciprofloxacin 1000 mg ER Tablets of Dr. Reddy's Under Non-Fasting Conditions

NCT01372358
View directory record Official record
Conditions
Fed
Interventions
CIPRO®XR
Drug
Lead sponsor
Dr. Reddy's Laboratories Limited
Industry
Eligibility
18 Years to 45 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 12, 2011 · Synced Sep 28, 2026, 5:38 PM EDT
Completed Phase 2 Interventional Results available

Phase 2b Study of KBP-5074 in Subjects With Uncontrolled Hypertension and Advanced Chronic Kidney Disease

NCT03574363
View directory record Official record
Conditions
Chronic Kidney Diseases, Hypertension
Interventions
KBP-5074 0.25 mg tablet, KBP-5074 0.5 mg tablet
Drug
Lead sponsor
KBP Biosciences
Industry
Eligibility
18 Years to 85 Years
Enrollment
162 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
2
States / cities
Princeton, New Jersey • Morrisville, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 29, 2025 · Synced Sep 28, 2026, 5:38 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study of Use of Ella®, an Emergency Contraceptive, Under Simulated OTC Conditions

NCT03208985
View directory record Official record
Conditions
Emergency Contraception
Interventions
Use Phase (Ulipristal Acetate, 30 mg)
Drug
Lead sponsor
HRA Pharma
Industry
Eligibility
Female only
Enrollment
1,270 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
34
States / cities
Rancho Cucamonga, California • Boulder, Colorado • Denver, Colorado + 27 more
Source: ClinicalTrials.gov public record
Updated Dec 1, 2022 · Synced Sep 28, 2026, 5:38 PM EDT
Terminated Phase 3 Interventional Results available

Losmapimod Safety and Efficacy in COVID-19

NCT04511819
View directory record Official record
Conditions
COVID-19
Interventions
Losmapimod oral tablet, Placebo oral tablet
Drug
Lead sponsor
Fulcrum Therapeutics
Industry
Eligibility
40 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
7
States / cities
Irvine, California • Miami, Florida • Tampa, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2024 · Synced Sep 28, 2026, 5:38 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

An Emotion Regulation Intervention for Early Adolescent Risk Prevention

NCT03430570
View directory record Official record
Conditions
Risk Behavior, Risk Reduction, Emotion Regulation
Interventions
Tablet TRAC Emotion Regulation Intervention
Behavioral
Lead sponsor
Rhode Island Hospital
Other
Eligibility
12 Years to 14 Years
Enrollment
85 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Dec 5, 2019 · Synced Sep 28, 2026, 5:38 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Higher Neural Changes Following Anticholinergic, Beta 3 Agonist, or Placebo in Patients With Overactive Bladder

NCT03817931
View directory record Official record
Conditions
Overactive Bladder, Dementia, Lower Urinary Tract Symptoms, Incontinence, Urge
Interventions
Anticholinergic, Beta-3 Agonists, Adrenergic, Functional magnetic resonance imaging (fMRI), Rey Auditory Verbal Learning Test (RAVLT)
Drug · Diagnostic Test
Lead sponsor
Baylor Research Institute
Other
Eligibility
18 Years to 90 Years · Female only
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
2
States / cities
Houston, Texas • Temple, Texas
Source: ClinicalTrials.gov public record
Updated Feb 1, 2024 · Synced Sep 28, 2026, 5:38 PM EDT
Active, not recruiting Phase 2 Interventional

A Study to Evaluate the Effect of Venetoclax on Participants Receiving a Covalent Bruton's Tyrosine Kinase Inhibitor (cBTKi) for First-line Chronic Lymphocytic Leukemia (1L CLL) to Achieve Deep Durable Remissions to Allow Off-treatment Period

NCT06524375
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia
Interventions
Venetoclax, cBTKi Monotherapy
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
20
States / cities
Springdale, Arkansas • Aurora, Colorado • Jacksonville, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Sep 27, 2026 · Synced Sep 28, 2026, 5:38 PM EDT
Completed Phase 2 Interventional

Efficacy and Safety of Circadin for Non-24 Hour Sleep-Wake Disorder in Totally Blind Subjects

NCT00972075
View directory record Official record
Conditions
Non-24 Hour Sleep-Wake Disorder, Blindness
Interventions
melatonin (Circadin), placebo
Drug
Lead sponsor
Neurim Pharmaceuticals Ltd.
Industry
Eligibility
20 Years to 80 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
2
States / cities
Atlanta, Georgia • New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 8, 2009 · Synced Sep 28, 2026, 5:38 PM EDT
Completed Phase 3 Interventional

A Study to Assess the Long-term Safety and Efficacy of AXS-05 in Subjects With Alzheimer's Disease Agitation

NCT04947553
View directory record Official record
Conditions
Agitation in Patients With Dementia of the Alzheimer's Type, Alzheimer Disease, Agitation, Psychomotor
Interventions
AXS-05 (dextromethorphan-bupropion), Placebo
Drug
Lead sponsor
Axsome Therapeutics, Inc.
Industry
Eligibility
65 Years to 90 Years
Enrollment
456 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
45
States / cities
Peoria, Arizona • Tempe, Arizona • Long Beach, California + 35 more
Source: ClinicalTrials.gov public record
Updated Dec 7, 2025 · Synced Sep 28, 2026, 5:38 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of the Effect of Itraconazole and Phenytoin on Calderasib (MK-1084) in Healthy Adults (MK-1084-008)

NCT06719557
View directory record Official record
Conditions
Healthy
Interventions
Calderasib, Itraconazole, Phenytoin
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
19 Years to 55 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Feb 10, 2026 · Synced Sep 28, 2026, 5:38 PM EDT
Recruiting Not applicable Interventional

MOMs Chat and Care Study

NCT06335381
View directory record Official record
Conditions
Severe Maternal Morbidity
Interventions
Maternal Health Education Resources, Prenatal Telehealth Visits, Postpartum Telehealth Visits, Home Blood Pressure Monitor, Fitbit
Other · Behavioral
Lead sponsor
Northwell Health
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
674 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Manhasset, New York
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Sep 28, 2026, 5:38 PM EDT
Terminated Phase 4 Interventional Results available

Effects of Atorvastatin on Myonecrosis

NCT00344019
View directory record Official record
Conditions
Coronary Disease
Interventions
Placebo Oral Tablet, Atorvastatin 80mg, Screening
Drug · Other
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 1, 2018 · Synced Sep 28, 2026, 5:38 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of Oral IXAZOMIB in Combination With Lenalidomide and Dexamethasone in Participants With Newly Diagnosed Multiple Myeloma

NCT01383928
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Ixazomib, Lenalidomide, Dexamethasone
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
20
States / cities
Berkeley, California • Duarte, California • Stanford, California + 15 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2019 · Synced Sep 28, 2026, 5:38 PM EDT
Recruiting Phase 3 Interventional

A Clinical Study of Molnupiravir to Prevent Severe Illness From Coronavirus Disease 2019 (COVID-19) in People Who Are High Risk (MK-4482-023)

NCT06667700
View directory record Official record
Conditions
Coronavirus Disease (COVID-19)
Interventions
Molnupiravir, Placebo
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
3,082 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
71
States / cities
Cullman, Alabama • Paradise Valley, Arizona • Phoenix, Arizona + 58 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Sep 28, 2026, 5:38 PM EDT
Completed Phase 2 Interventional Results available

A Phase 2, Placebo-Controlled Study To Evaluate The Efficacy And Safety Of PF-00489791 In Patients With Type 2 Diabetes And Overt Nephropathy

NCT01200394
View directory record Official record
Conditions
Diabetic Nephropathies
Interventions
PF-00489791, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
256 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
63
States / cities
Huntsville, Alabama • Glendale, Arizona • Tempe, Arizona + 46 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2019 · Synced Sep 28, 2026, 5:38 PM EDT